Ya-Min Cheng

National Cheng Kung University

Papers

1

Total Citations

10

H-Index

1

About

Dr. Ya-Min Cheng is a leading gynecologic oncologist whose research focuses on optimizing treatment strategies for ovarian, tubal, and peritoneal cancers. Her most significant contribution is the landmark ROBOT study, an eight-year real-world investigation that evaluated the long-term efficacy and safety of adding bevacizumab to standard chemotherapy in Asian patients. This work, published in 2020 with 10 citations, provided crucial insights into the prognostic impacts and adverse effects of this targeted therapy in a population often underrepresented in clinical trials. By analyzing consecutive patient records, Dr. Cheng’s research bridges the gap between controlled trial data and everyday clinical practice, offering evidence-based guidance for frontline and relapse treatment. Her dedication to real-world evidence has helped refine therapeutic protocols, improving outcomes for women battling these challenging malignancies. Dr. Cheng’s work stands as a vital resource for clinicians seeking to personalize care and manage treatment-related toxicities effectively.

Research Focus

Key Achievements

1
H-Index
1
Papers
10
Total Citations
10
Avg Citations/Paper
🏆 Most Cited Paper
Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience
10 citations · 2020
📈 Most Prolific Year: 2020 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: National Cheng Kung University

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago